industry symposia

PROGRAMME of
INDUSTRY
SYMPOSIA
on the occasion
of the 51st Annual Meeting
of the European Association
for the Study of Diabetes
STOCKHOLM
14 September 2015
17 September 2015
INTERPLAN
media & service gmbh
www.easd-industry.com
CONTENT
Individualised
patient care in
Type 2 diabetes:
Translating science
to practice
Symposium on the occasion of the
51st Annual Meeting of the European
Association for the Study of Diabetes
10:30–11:00
Welcome and introduction: why and
when should we treat Type 2 diabetes?
C Mathieu (Belgium), J Vora (UK)
11:00–11:30
Treatment decisions for our patients:
what are the considerations?
R Pratley (US)
11:30–11:55
Weight gain in the treatment of
Type 2 diabetes: is it inevitable?
J Wilding (UK) 11:55–12:20
The kidneys in Type 2 diabetes:
challenges and opportunities?
M Cooper (Australia)
12:20–12:45
Can we delay escalation to insulin
therapy?
T Vilsbøll (Denmark)
12:45–13:00
Monday 14 September 2015,10:30–16:30
Heding Hall, Stockholmsmässan
Making the right choice at the right time with our patients is
key to ensuring their future wellbeing. But with the vast array of
potential therapies now available, and the science behind diabetes
management advancing rapidly, how can we ensure we are
pursuing the optimal treatment approach with each individual?
What steps should we take to stop
progression of poor glucose control?
Panel discussion led by C Mathieu (Belgium),
J Vora (UK)
13:00–14:00
Lunch
14:00–14:10
Welcome back
C Mathieu (Belgium), J Vora (UK)
14:10–14:40
In this symposium we will translate the science and bring
our patients into focus through interactive talks, interviews,
discussions and Q&A sessions with world-leading experts.
Safety of novel therapies in
Type 2 diabetes: what’s the latest?
Join us to explore key questions in patient management, and
share views and clinical experience with the aim of raising
the standard of care for patients living with diabetes.
What is the physiological basis for
combining therapies?
J Meier (Germany)
14:40–15:05
J Holst (Denmark)
15:05–15:35
Join us and be part of the debate!
Why not combine earlier?
J Seufert (Germany)
15:35–16:00
What can we expect for future
management of diabetes?
M Davies (UK)
Professor Chantal Mathieu
University of Leuven, Leuven, Belgium (Co-chair)
Professor Jiten Vora
Head of External Scientific Affairs, AstraZeneca, and
Professor of Endocrinology, University of Liverpool,
Liverpool, UK (Co-chair)
16:00–16:25
How should we make the right
treatment choices for our patients?
Panel discussion led by C Mathieu (Belgium),
J Vora (UK)
16:25–16:30
Wrap up and close
What science can do
2
Organised and funded by AstraZeneca
C Mathieu (Belgium), J Vora (UK)
May 2015 – ATLAS ID: 762.302,011
Expiry date: 18 September 2015
WELCOME ADDRESS
Dear Guests,
It will be a great honour and pleasure to welcome you to the 51st EASD Annual Meeting from 14 – 18
September 2015 in Stockholm, Sweden.
For many years, an integral part of the EASD Congress has been the symposia on the occasion of
our Annual Meeting which have provided state-of-the-art information on developments in diabetes
care and research.
These symposia offer a range of valuable information and knowledge on clinical and basic research
in the field of diabetes, new and upcoming treatments and major developments in the field of diabetes
and its complications.
They attract opinion leaders, academic researchers, physicians and other health care professionals and offer an excellent
platform for discussion and the opportunity to learn about new research as well as the latest news and updates in the
world of diabetes research and care.
Beginning on September 14 with the industry symposia, an international audience of academics, researchers and physicians
from over 100 countries will descend on the Stockholmsmässan in Stockholm.
For the first time in the history of the EASD Congress, I have the pleasure to invite you to attend the industry mini symposia,
which take place in the afternoon of 14 September, and the industry evening symposia, which take place directly after the
EASD Scientific Programme on 17 September.
These sessions provide an outstanding forum for interaction, communication, education and collaboration and are an
excellent introduction to the official EASD Scientific Programme which will begin on September 15.
On behalf of EASD and the Local Organising committee, I encourage you to actively take part in the symposia on the
occasion of the Annual Meeting of the European Association for the Study of Diabetes during what promises to be an
outstanding 51st EASD Annual Meeting.
I look forward to welcoming you to Stockholm.
Prof. Andrew J.M. Boulton
President, EASD
3
CONTENT
Schedule................................................................................................................................. 5
Hall Overview....................................................................................................................... 6
Programme of Industry Symposia.............................................................................7
Sanofi Diabetes
Different patients, different needs: towards an integrated care approach in diabetes care........................................... 8
Novo Nordisk
Evolving perspectives in treating diabetes and obesity................................................................................................ 10
AstraZeneca
Individualised patient care in Type 2 diabetes: translating science to practice............................................................ 12
Boehringer Ingelheim & Eli Lilly and Company
Getting to the heart of Type 2 Diabetes........................................................................................................................ 13
Novartis Pharmaceuticals
The future of diabetes: opportunities and challenges................................................................................................... 14
DexCom
Dexcom Continuous Glucose Monitoring in 2015 – Clinical Practice, Technology Innovations and Market Access.......... 16
Pfizer
Translational Pursuits.................................................................................................................................................... 17
Zydus Cadila
SAROGLITAZAR – A breakthrough discovery in the management of metabolic disorders.......................................... 18
Merck Sharp & Dohme
Lessons Learned from the TECOS CV Safety Trial and the Evolving Role of DPP-4 Inhibitors
in the Treatment of Patients with Type 2 Diabetes........................................................................................................ 19
Amgen
Diabetic dyslipidemia, cardiovascular disease and PCSK9 inhibition with evolocumab: 4 key questions................. 20
Becton Dickinson & Company Inc.
Optimizing Insulin Pump Therapy: Infusion Set Failures and Silent Occlusions.......................................................... 22
Takeda
Should type 2 diabetes (T2D) management be more of a priority in post-acute coronary syndrome (ACS) patients?..... 24
Roche Diabetes Care
How much can technology support Personalized Diabetes Management.................................................................. 26
Medscape Education supported by an independent educational grant from Janssen
Should SGLT2 Inhibitors Be An Integral Part of a Personalized Treatment Plan for Type 2 Diabetes?....................... 28
Abbott
One year with flash glucose monitoring – Perspectives from different stakeholders in diabetes care. What’s next?........ 29
Programme of Industry Mini Symposia................................................................. 30
LG Life Sciences
What is the Optimized treatment for T2DM patients?................................................................................................. 30
Aegerion
The Metabolic Chaos of Lipodystrophy – Finding the Order Within . ......................................................................... 32
Eli Lilly and Company
Challenges in Comprehensive Lipid Management...................................................................................................... 33
Programme of Industry Evening Symposia........................................................ 35
Novo Nordisk
GLP-1 receptor agonists: liraglutide 3.0 mg in weight management.......................................................................... 35
Boehringer Ingelheim & Eli Lilly and Company
EMPA-REG OUTCOME®: Implications for management of patients with Type 2 Diabetes......................................... 36
Merck Sharp & Dohme
The TECOS CV Safety Trial and the Lessons Learned for Treatment of Patients with Type 2 Diabetes
and Cardiovascular Disease........................................................................................................................................ 38
Eli Lilly and Company
The Patient in Mind: new perspectives on injectable therapy for type 2 diabetes...................................................... 39
Badges during Symposia Days....................................................................................41
IMPRINT.................................................................................................................................... 42
4
SCHEDULE
Monday, 14 September 2015 09:00
Keen Hall
Hellerström Hall
10:00
Industry Symposia
11:00
12:00
13:00
14:00
15:00
16:00
Sanofi Diabetes
Page 8
Novo Nordisk
Page 10
Heding Hall
AstraZeneca
Page 12
Peltonen-Palotie
Hall
Boehringer Ingelheim &
Eli Lilly and Company
Page 13
Jacobsohn Hall
Novartis
Page 14
Meyer-Schwickerath
Hall
DexCom
Amgen
Page 16
Page 20
Rahbar Hall A
Zydus Cadila
Doniach Hall
Merck Sharp & Dohme
Page 18
Page 19
Rahbar Hall B
Becton Dickinson &
Company, Inc.
Pfizer
Page 17
Page 22
Kimmelstiel Hall
Takeda
Bouchardat Hall
Roche Diabetes Care
Loubatière Hall
Medscape Education
Sterne Hall
Abbott
Page 24
Page 26
Page 28
Page 29
Monday, 14 September 2015 Industry Mini Symposia
17:00 – 18:00
Schmidt Hall
Hodgkin Hall
Pirart Hall
Sanger Hall
LG Life Sciences
Page 30
Aegerion
Page 32
Eli Lilly and Company
Page 33
AstraZeneca
Thursday, 17 September 2015 Industry Evening Symposia
19:00
Loubatière Hall
20:00
Novo Nordisk
Page 35
Meyer-Schwickerath Boehringer Ingelheim & Eli Lilly and Company
Page 36
Hall
Kimmelstiel Hall
Elite Hotel
Marina Tower
Merck Sharp & Dohme
Page 38
Eli Lilly and Company
Page 39
5
21:00
HALL OVERVIEW
EXIT
ONLY
Hellerström
Hall
Scientific Halls
Symposia Halls
Exhibition
Jacobsohn
Hall
Rahbar
Hall B
Doniach
Hall
Associations’ Village
Rahbar
Hall A
POSTER
EXHIBITION
MeyerSchwickerath
Hall
Sterne Hall
Bouchardat
Hall
Loubatière
Hall
Schmidt
Hall
Registration
Area
Heding Hall
Registration
Area
MAIN
ENTRANCE
to First Floor
Älvsjö Station
6
Hodgkin
Hall
Kimmelstiel Hall
Keen
Hall
Peltonen-Palotie
Hall
Sanger
Hall
Pirart
Hall
Programme of
Industry Symposia
INDUSTRY SYMPOSIA
Different patients, different needs:
towards an integrated care approach
in diabetes CAre
Monday, 14 SEPTEMBER 2015 09:00 – 16:00
Keen Hall
09:00 – 09:10
Welcome and introduction
Richard Bergenstal (USA), Lars Rydén (Sweden)
09:10 – 09:20
Different patients, different needs, different approaches
Athena Philis-Tsimikas (USA)
OPTIMISING AND ADVANCING BASAL INSULIN
09:20 – 09:45
The evolution of basal insulin: New insights
Alice Cheng (Canada)
09:45 – 10:10
When it’s time to intensify: What are the options?
Robert Henry (USA)
10:10 – 10:30
Interactive audience discussion and patient summary
All
10:30 – 10:50
Break
UNDERSTANDING AND MANAGING RISK IN DIABETES CARE
10:50 – 11:35
Too high or too low: The risks of hyperglycaemia vs hypoglycaemia
Pratik Choudhary (UK), Silvio Inzucchi (USA)
11:35 – 12:00
Getting to the heart of the matter: Understanding cardiovascular risk in diabetes
Lars Rydén (Sweden)
12:00 – 12:25 Controlling cholesterol in diabetes
Bertrand Cariou (France)
12:25 – 12:45
Interactive audience discussion and patient summary
All
12:45 – 13:45
Lunch
EXPANDING THE HORIZONS OF DIABETES CARE
13:45 – 13:50
Overview of afternoon session
Richard Bergenstal (USA), Lars Rydén (Sweden)
13:50 – 14:00
Different patients, different needs, different approaches
Partha Kar (UK)
14:00 – 14:25
Beyond the prescription: Setting, achieving and maintaining target
Athena Philis-Tsimikas (USA)
14:25 – 14:50
Beyond pharmacotherapy: Technologies that improve how patients
interact with their disease
Steve Edelman (USA)
14:50 – 15:15 Beyond the clinic: How can we connect with our patients?
Partha Kar (UK)
15:15 – 15:40 Patient integrated care: Comprehensive support for better patient outcomes
Richard Bergenstal (USA), Lars Rydén (Sweden)
15:40 – 16:00 Patient summary + closing remarks
All
Organised by: Sanofi Diabetes
8
JOIN US FOR
OUR SYMPOSIUM
on the occasion of the 51st EASD Annual Meeting
MONDAY 14th
SEPTEMBER 2015
Images shown are models used for illustrative purposes only
09.00 –16.00
Keen Hall
Stockholm International
Fairs & Congress Center
Stockholm
DIFFERENT PATIENTS
DIFFERENT NEEDS:
09.00 –16.00
Optimizing and advancing basal insulin
Understanding and managing risk in diabetes care
Expanding the horizons of diabetes care
Please visit us at booth B06:31, hall B
for further information
SAGLB.DIA.15.06.0341 Date of preparation: June 2015
towards an integrated care
approach in diabetes
INDUSTRY SYMPOSIA
evolving perspectives in
treating diabetes and obesity
Monday, 14 SEPTEMBER 2015 09:00 – 13:10
Hellerström Hall
MORNING SESSION
09:00 – 09:10 Welcome
Host and chair: Bo Ahrén (Sweden)
09:10 – 09:30 Is intensive behavioural therapy enough in obesity management?
Michael Lean (UK)
09:30 – 09:45 Mode of action of liraglutide 3.0 mg in weight management
Niels Vrang (Denmark)
09.45 – 10:00 Focused weight management strategies – update on clinical practice
Nicholas Finer (UK)
10:00 – 10:15 The SCALE phase 3a clinical trial programme – benefits on secondary
outcomes
Luc Van Gaal (Belgium)
10:15 – 10:45 Coffee
10:45 – 11:05 Personalising the choice of anti-obesity medication (responder analyses)
Donna Ryan (USA)
11:05 – 11:20 Mechanisms in cardiovascular effects of GLP-1
Mansoor Husain (Canada)
11:20 – 11:45 Managing diabetes in special populations
Melanie Davies (UK)
11:45 – 12:10 Panel discussion
12:10 – 13:10 Lunch
Organised by: Novo Nordisk
10
INDUSTRY SYMPOSIA
evolving perspectives in
treating diabetes and obesity
Monday, 14 SEPTEMBER 2015 13:10 – 15:20
Hellerström Hall
AFTERNOON SESSION
13:10 – 13:15 Welcome
Host: Bo Ahrén (Sweden), Chair: Tina Vilsbøll (Denmark)
13:15 – 13:35 Hypoglycaemia anno 2015: what we have learned
Simon Heller (UK)
13:35 – 13:55 What is new in insulin treatment?
Tim Heise (Germany) and Christopher Sorli (USA)
13:55 – 14:15 A new choice for diabetes treatment – the dual approach
Stephen Gough (UK)
14:15 – 14:35 The clinical potential of the dual approach
John Buse (USA)
14:35 – 14:50 Panel discussion
14:50 – 15:10 Cardiovascular outcomes trials in diabetes – what have we learned and where are we heading?
Marc Pfeffer (USA)
15:10 – 15:20 Closure
Tina Vilsbøll (Denmark)
Organised by: Novo Nordisk
11
INDUSTRY SYMPOSIA
Individualised patient care in Type 2 diabetes:
translating science to practice
Monday, 14 SEPTEMBER 2015 10:30 – 16:30
Heding Hall
10:30 – 11:00
Welcome and introduction
Why and when should we treat Type 2 diabetes?
Chantal Mathieu (Belgium) / Jiten Vora (UK)
11:00 – 11:30
Treatment decisions for our patients: what are the considerations?
Richard Pratley (USA)
11:30 – 11:55
Weight gain in the treatment of Type 2 diabetes: is it inevitable?
John Wilding (UK)
11:55 – 12:20
The kidneys in Type 2 diabetes: challenges and opportunities?
Mark Cooper (Australia)
12:20 – 12:45
Can we delay escalation to insulin therapy?
Tina Vilsbøll (Denmark)
12:45 – 13:00
What steps should we take to stop progression of poor glucose control?
Chantal Mathieu (Belgium) / Jiten Vora (UK)
13:00 – 14:00
Lunch
14:00 – 14:10
Welcome back
Chantal Mathieu (Belgium) / Jiten Vora (UK)
14:10 – 14:40
Safety of novel therapies in Type 2 diabetes: what’s the latest?
Juris Meier (Germany)
14:40 – 15:05
What is the physiological basis for combining therapies?
Jens Holst (Denmark)
15:05 – 15:35
Why not combine earlier? Jochen Seufert (Germany)
15:35 – 16:00
What can we expect for future management of diabetes?
Melanie Davies (UK)
16:00 – 16:25
How should we make the right treatment choices for our patients?
Chantal Mathieu (Belgium) / Jiten Vora (UK)
16:25 – 16:30
Wrap up and close
Chantal Mathieu (Belgium) / Jiten Vora (UK)
Organised by: AstraZeneca
12
INDUSTRY SYMPOSIA
Getting to the heart
of Type 2 Diabetes
Monday, 14 SEPTEMBER 2015 14:00 – 16:05
Peltonen-Palotie Hall
14:00 – 14:05
Welcome
Co-chairs: Clifford Bailey (UK) and Nikolaus Marx (Germany)
Session 1: 14:05 – 14:25
The broken hearted – CV risk and T2D management
Tackling CV risk in T2D – time for a change?
Kausik Ray (UK)
14:25 – 14:50
New horizons for managing CV risk with anti-hyperglycaemic agents
Naveed Sattar (UK)
14:50 – 15:10
The evolving landscape of CV outcome trials in T2D
Nikolaus Marx (Germany)
15:10 – 15:25
Q&A
Session 1 faculty
Session 2: Healing heartache – does emotional engagement with BASAL insulin therapy improve outcomes?
15:25 – 15:40
How successful is basal insulin therapy in clinical reality?
Christophe de Block (Belgium)
15:40 – 15:55
Can the empathy of healthcare professionals increase the success of
basal insulin treatment in T2D?
Mark Peyrot (USA)
15:55 – 16:00
Q&A
Session 2 faculty
16:00 – 16:05
Closing remarks
Clifford Bailey (UK)
Organised by: Boehringer Ingelheim & Eli Lilly and Company
13
INDUSTRY SYMPOSIA
The future of diabetes:
opportunities and challenges
Monday, 14 SEPTEMBER 2015 Chair: Anthony Barnett (UK)
Guest speaker: Sir Michael Hirst (UK)
Faculty members: Kamlesh Khunti (UK)
Mark Cooper (Australia)
Focke Ziemssen (Germany)
Matthias Blüher (Germany)
13:30 – 14:30
PART 1: The vision – opportunities and challenges
14:30 – 14:50
Refreshment break
14:50 – 17:00
PART 2: The reality - opportunities and challenges
14:50 – 15:50
15:50 – 17:00
Will optimised diabetes care be accessible in the future?
Will we be able to prevent the future?
Organised by: Novartis Pharmaceuticals
14
13:30 – 17:00
Jacobsohn Hall
THE
THEFUTURE
FUTURE
OF
OFDIABETES
DIABETES
Opportunities
&&
challenges
challenges
Opportunities
A Novartis-sponsored
A Novartis-sponsored
symposium
symposium
onon
thethe
occasion
occasion
of of
thethe
st
st Annual
51st51Annual
Meeting
Meeting
of of
thethe
European
European
Association
Association
forfor
thethe
Study
Study
of of
Diabetes
Diabetes
14 14
September
September
2015
2015
13:30–17:00
13:30–17:00
Jacobsohn
Jacobsohn
Hall,
Hall,
Stockholmsmässan,
Stockholmsmässan,
Stockholm,
Stockholm,
Sweden
Sweden
Agenda
13:30–14:30Agenda
PART 1: The vision - opportunities and challenges
nett (Chair),
UK
Faculty
Faculty
Agenda
irst, UK
14:30–14:50
Refreshment
break
unti, UK
13:30–14:30
13:30–14:30
PART
PART
1: The
1: The
vision
vision
- opportunities
- opportunities
and
and
challenges
challenges
Anthony
Anthony
Barnett
Barnett
(Chair),
(Chair),
UKUK
Australia
SirSir
Michael
Michael
Hirst,
Hirst,
UKUK
PART 2: The
reality - break
opportunities
and challenges
14:30–14:50
Refreshment
Refreshment
break
Kamlesh
Kamlesh
Khunti,
Khunti,
UKUK 14:50–17:00 14:30–14:50
sen, Germany
Mark
Mark
Cooper,
Cooper,
Australia
Australia
üher, Germany
14:50–17:00
PART
PART
2: diabetes
The
2: The
reality
reality
-care
opportunities
- opportunities
and
and
challenges
challenges
Focke
Focke
Ziemssen,
Ziemssen,
Germany
Germany
14:50–15:50 14:50–17:00
Will optimised
be accessible
Matthias
Matthias
Blüher,
Blüher,
Germany
Germany
in the future?
14:50–15:50
14:50–15:50
14:50–15:50
15:50–17:00
Will
Will
optimised
optimised
diabetes
diabetes
care
care
bebe
accessible
accessible
in in
thethe
future?
future?
Will we be able to prevent the future?
15:50–17:00
15:50–17:00
Will
wewe
bebe
able
able
to to
prevent
prevent
thethe
future?
future?
Will
This symposium may include
discussion
on products
and/or
indications
stilland/or
Item
code: GLCM/GAL/0033
| GLRET/LUC/0373
This symposium
This
may include
may
discussion
discussion
on products
on
and/or
indications
indications
still still
Item code:
Item
GLCM/GAL/0033
GLCM/GAL/0033
| GLRET/LUC/0373
|| GLRET/LUC/0373
This symposium
symposium
may include
include
discussion
on products
products
and/or
indications
still
Item code:
code:
GLCM/GAL/0033
GLRET/LUC/0373
under investigation. Physicians
mayinvestigation.
only prescribe
products
in
accordance
| SE1505339866
underunder
investigation.
Physicians
Physicians
may only
may
only
products
products
in accordance
in
| SE1505339866
SE1505339866
under
investigation.
Physicians
may prescribe
only prescribe
prescribe
products
in accordance
accordance
|| SE1505339866
with their prescribing information.
Prescribing
information
differs
from
country
Date
of
preparation:
May
2015.
©2015
Novartis
with their
with
prescribing
their
prescribing
information.
information.
Prescribing
Prescribing
information
information
differs
differs
from
country
from
country
Date
Date
of
preparation:
of
preparation:
May
2015.
May
2015.
©2015
Novartis
Novartis
with their prescribing information. Prescribing information differs from country
Date of preparation: May 2015. ©2015
©2015
Novartis
country.
to
country.
Please
Please
refer refer
to your
to
your
prescribing
prescribing
information.
information.
Pharma
AG, Basel,
CH-4002
AG,
Basel,Basel,
Switzerland
Switzerland
to country. Please refer to to
your
prescribing
information.
Pharma AG,Pharma
CH-4002
Switzerland
tolocal
country.
Please
refer
to local
your local
local
prescribing
information.
Pharma
AG, CH-4002
CH-4002
Basel,
Switzerland
INDUSTRY SYMPOSIA
Dexcom Continuous Glucose Monitoring
in 2015 – Clinical Practice, Technology
Innovations and Market Access
Monday, 14 SEPTEMBER 2015 Moderator: 10:00 – 10:50
10:00 – 12:30
Meyer-Schwickerath Hall
Peter Adolfsson (Sweden)
Using Dexcom CGM in Clinical Practice – Education and Medical
Management
Peter Adolfsson (Sweden)
10:50 – 11:40
Current and Future Dexcom CGM Technology Innovations
Jake Leach (USA)
11:40 – 12:30
Continuous Glucose Monitoring – Cost Modeling and Reimbursement
Claudia Graham (USA)
Organised by: DexCom
16
INDUSTRY SYMPOSIA
Translational Pursuits
Monday, 14 SEPTEMBER 2015 10:00 – 12:30
Rahbar Hall B
Host
Prof. Morrie Birnbaum (USA)
CSO, Pfizer CVMED
Chair
Dr Julia Brosnan (USA)
10:00 – 10:10
Welcome and Opening
Julia Brosnan (USA)
10:10 – 10:40
A fine-tuned classification of diabetes – steps towards individualized
medicine
Leif Groop (Sweden)
10:40 – 11:20
Rare and Frequent DNA Variation and Precision Diabetic Medicine
Philippe Froguel (France)
11:20 – 11:50
Building a target hypothesis: genetic associations are only the start
Daniel Ziemek (Germany)
11:50 – 12:30
Diamonds in the Dirt – using human genetics to Define Biology and Guide .
translation in type 2 Diabetes
Mark McCarthy (UK)
Organised by: Pfizer
17
INDUSTRY SYMPOSIA
SAROGLITAZAR – A breakthrough DISCOVERY
in the management of metabolic disorders
Monday, 14 SEPTEMBER 2015 Chairs
Banshi Saboo (India), S. K. Sharma (India)
14:30 – 14:50
Diabetic dyslipidemia & its management:
Review of current therapeutic options
Charles Burant (USA)
14:50 – 15:10 PPAR agonism: Role in metabolic disorders
Walter Wahli (Switzerland)
15:10 – 15:30 Saroglitazar: Concept to clinic
Shashank R. Joshi (India)
15:30 – 15:50
Saroglitazar: An endocrinologist’s perspective
Anil Bhansali (India)
15:50 – 16:10
Saroglitazar: A cardiologist’s perspective
Saumitra Ray (India)
16:10 – 16:30 Saroglitazar: NASH perspective
Sujoy Ghosh (India)
16:30 – 17:00
Panel discussion
Organised by: Zydus Cadila
18
14:30 – 17:00
Rahbar Hall A
INDUSTRY SYMPOSIA
Lessons Learned from the TECOS CV Safety Trial
and the Evolving Role of DPP-4 Inhibitors in the
Treatment of Patients with Type 2 Diabetes
Monday, 14 SEPTEMBER 2015 14:30 – 17:00
Doniach Hall
14:30 – 14:35 Chair Welcome and Opening Remarks
Co-Chairs: Rury Holman (UK), Michel Komajda (France)
14:35 – 15:05 Are we Treating Patients Based on the Evidence?
Previous Cardiovascular Trials: Michel Komajda (France)
DPP-4 CV Safety Trials: Michael Nauck, (Germany)
15:05 – 15:20 Audience Vote and Discussion led by Chairmen
15:20 – 15:40 DPP-4 Inhibitors: What is the Latest Science?
Carolyn Deacon (Denmark)
15:40 – 15:50 Q&A
15:50 – 16:20 Lessons Learned from the TECOS CV Safety Trial: The Role of Sitagliptin
in the Treatment of Cardiovascular Patients with Type 2 Diabetes
Rury Holman (UK)
16:20 – 16:30 Q&A
16:30 – 16:55 Specialty Dialogue: Treatment of Patients with Type 2 Diabetes from an
Endocrinology, Nephrology and Cardiology View
Faculty
16:55 – 17:00 Final Comments and Summary
Chairmen: Rury Holman (UK), Michel Komajda (France)
Organised by: Merck Sharp & Dohme
19
INDUSTRY SYMPOSIA
Diabetic dyslipidemia, cardiovascular
disease and PCSK9 inhibition with
evolocumab: 4 key questions
Monday, 14 SEPTEMBER 2015 14:30 – 17:00
Meyer-Schwickerath Hall
14:30 – 14:35
Welcome and introduction
Marja-Riitta Taskinen (Finland)
Handrean Soran (UK)
14:35 – 15:05
Targeting dyslipidemia in diabetes, is it important?
Neil Poulter (UK)
15:05 – 15:35
Patients who cannot tolerate a maximum dose of statins,
what should we do?
Ulrich Laufs (Germany)
15:35 – 16:05
What is PCSK9 and why should you be interested in it?
John Chapman (France)
16:05 – 16:45
Debate: Is LDL-C reduction more important than glucose lowering
in diabetes?
For: Kausik Ray (UK)
Against: Naveed Sattar (UK)
16:45 – 17:00
Panel questions and closing remarks
Marja-Riitta Taskinen (Finland)
Handrean Soran (UK)
Organised by: Amgen
20
Symposium on the occasion of the 51st Annual Meeting
of the European Association for the Study of Diabetes
INDUSTRY SYMPOSIA
Diabetic dyslipidemia, cardiovascular disease
and PCSK9 inhibition with evolocumab:
4 key questions
monday 14 September 2015, 14.30–17.00
Meyer-Schwickerath Hall, Stockholmsmässan, Stockholm, Sweden
Programme
Welcome and introduction
Marja-Riitta Taskinen, Finland and Handrean Soran, UK
Targeting dyslipidemia in diabetes, is it important?
Neil Poulter, UK
Patients who cannot tolerate a maximum dose of statins,
what should we do now?
Ulrich Laufs, Germany
What is PCSK9 and why should you be interested in it?
John Chapman, France
Debate: Is LDL-C reduction more important than
glucose lowering in diabetes?
For: Kausik Ray, UK Against: Naveed Sattar, UK
Panel questions and closing remarks
Marja-Riitta Taskinen, Finland and Handrean Soran, UK
refreshments will be available
prior to the symposium
Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland
21
© 2015 Amgen Inc. All rights reserved.
EUHQ-NP-145-0615-107185 June 2015
INDUSTRY SYMPOSIA
Optimizing Insulin Pump Therapy:
Infusion Set Failures and Silent Occlusions
Monday, 14 SEPTEMBER 2015 14:30 – 17:00
Rahbar Hall B
14:00 – 14:30 Registration
14:30 – 14:35 Welcome, Faculty Disclosures and Program Objectives
14:35 – 14:40 Pre-test Using Audience Response System
14:40 – 15:00 Current Perspectives on Insulin Dynamics in the Subcutaneous Space
Prof. Lutz Heinemann (Germany)
15:00 – 15:30 The Science of Infusion Sets: Gaps in Clinical Evidence
Dr. Bruce A. Buckingham (USA)
15:30 – 15:50 Paediatric Clinical Case
Prof. Thomas Danne (Germany)
15:50 – 16:10 New Insulin Infusion Set Technology
Dr. Laurence J. Hirsch (USA)
16:10 – 16:20 Toward the Artificial Pancreas: Clinical Perspectives on Opportunities
and Gaps
Prof. J. Hans De Vries (The Netherlands)
16:20 – 16:30 New Research: What the Future Holds
Dr. Aaron Kowalski (USA)
16:30 – 16:45 Demonstrations
16:45 – 16:50 Questions & Answers
16:50 – 16:55 Post-test Using Audience Response System
16:55 – 17:00
Closing Remarks
Organised by: Becton Dickinson & Company Inc.
22
A symposium on
the occasion of the
INDUSTRY
st
51 EASD Annual Meeting
SYMPOSIA
OPTIMIZING INSULIN
PUMP THERAPY
FACULTY
Bruce A. Buckingham, MD
(Co-Chair)
Professor of Pediatrics (Endocrinology)
Lucile Salter Packard Children’s Hospital
Los Gatos, California, USA
J. Hans De Vries, MD, PhD
(Co-Chair)
Lecturer & Consultant Endocrinologist
Department of Endocrinology
Academic Medical Centre
Amsterdam, The Netherlands
Thomas Danne, MD
Diabetes Centre for Children
and Adolescents
Janusz-Korczak-Allee 12
Hannover, Germany
Lutz Heinemann, PhD
Infusion Set Failures and
Silent Occlusions
MONDAY, 14 SEPTEMBER 2015
14:30–17:00
Rahbar Hall B
Stockholmsmässan
Stockholm, Sweden
EDUCATIONAL OBJECTIVES
After participating in the symposium, the learner will be able to:
• Recognize knowledge gaps and technical issues associated with the use of insulin
infusion sets, including flow interruptions with infusion sets
• Identify strategies to improve patient and healthcare professional knowledge gaps
around insulin infusion sets
• Review potential benefits of new infusion set technology in clinical care
Science & Co
Düsseldorf, Germany
AGENDA
Laurence J. Hirsch, MD
14:00–14:30
Registration and Light Refreshments
VP Worldwide Medical Affairs
Diabetes Care
Becton, Dickinson and Company
Franklin Lakes, New Jersey, USA
14:30–14:35
Welcome, Faculty Disclosures,
and Program Objectives
Aaron Kowalski, PhD
14:35–14:40
Pre-test Using Audience
Response System
Chief Mission Officer and VP, Research
JDRF
New York, New York, USA
Register at
www.bdsympo2015.com
For more information, please email
maryjo.holden@athenaedgroup.com
14:40–15:00
Current Perspectives on Insulin
Dynamics in the Subcutaneous Space
Lutz Heinemann, PhD
15:00–15:30
The Science of Infusion Sets:
Gaps in Clinical Evidence
Bruce A. Buckingham, MD
15:30–15:50
Paediatric Clinical Case
Thomas Danne, MD
16:10–16:20
Toward the Artificial Pancreas:
Clinical Perspectives on
Opportunities and Gaps
J. Hans De Vries, MD, PhD
16:20–16:30
New Research: What the Future Holds
Aaron Kowalski, PhD
16:30–16:45
Demonstrations
16:45–16:50
Questions & Answers
16:50–16:55
Post-test Using Audience
Response System
16:55–17:00
Closing Remarks
15:50–16:10
New Insulin Infusion Set Technology
Laurence J. Hirsch, MD
Provided by
Athena Education Group, LLC
Supported by
Becton, Dickinson and Company
23
BD, BD logo and all other trademarks are property of
Becton, Dickinson and Company © 2015 BD
INDUSTRY SYMPOSIA
Should type 2 diabetes (T2D) management be
more of a priority in post-acute coronary syndrome (ACS) patients?
Monday, 14 SEPTEMBER 2015 Chair: Ele Ferrannini (Italy)
14:30 – 14:45
Welcome
Ele Ferrannini (Italy)
14:45 – 15:10
The ACS patient journey: where does T2D fit in?
Jean-Claude Tardif (Canada)
14:30 – 17:00
Kimmelstiel Hall
15:10 – 15:50
Perspectives of diabetes and cardiovascular-risk management in
post-ACS T2D patients
· Cardiologist’s perspective
Stephen Nicholls (Australia)
· Diabetologist’s perspective
Jørgen Rungby (Denmark)
15:50 – 16:30
What do we know about the safety of oral anti-diabetics in post-ACS T2D .
patients? Exploring evidence from recent outcomes studies
Faiez Zannad (France)
16:30 – 16:55
Debating the optimal management of post-ACS T2D patients
All speakers, facilitated by Ele Ferrannini
16:55 – 17:00
Conclusions and close
Ele Ferrannini (Italy)
Organised by: Takeda
24
INDUSTRY SYMPOSIA
Should type 2 diabetes (T2D) management
be more of a priority in post-acute coronary
syndrome (ACS) patients?
Putting the spotlight on T2D management
in post-ACS patients
Chair: Professor Ele Ferrannini
Takeda-sponsored symposium
Kimmelstiel Hall,
Monday 14 September 2015; 14:30–17:00
On the occasion of the 51st Annual Meeting of the European
Association for the Study of Diabetes, Stockholm, Sweden,
14 – 18 September 2015
25
Job code: GLO/ALO/2015-00055
Date of preparation: May 2015
INDUSTRY SYMPOSIA
How much can technology support
Personalized Diabetes Management?
Monday, 14 SEPTEMBER 2015 14:30 – 17:00
Bouchardat Hall
Chairs: Rudy Bilous (UK) + Rolf Hinzmann (Germany)
14:30 – 14:40
Introduction
14:40 – 15:05
Surfing safely in the diabetes app tsunami
Ashleigh Walker (Canada)
15:05 – 15:30
The benefits mobile health solutions like the Accu-Chek® Connect system can bring to Personalized Diabetes Management
Fabio Broglio (Italy)
15:30 – 15:55
Personalized Diabetes Management today and tomorrow – options for better diabetes therapy
Matthias Axel Schweitzer (Germany)
15:55 – 16:20
First results of the Accu-Chek® Insight EU Study
Julia Mader (Austria)
16:20 – 16:45
CGM – Developments, indications, performance
Peter Adolfsson (Sweden)
16:45 – 17:00
Discussion and closing
Organised by: Roche Diabetes Care
26
INDUSTRY SYMPOSIA
New Accu-Chek® solutions for you
The Accu-Chek® Connect diabetes
management system
The Accu-Chek® Insight diabetes
therapy system
Better connected
for better decisions
Designed with
your patients’ lives
in mind
Visit us in Hall B at stand 10.31 and find out more
Experience what’s possible.
For more information about Accu-Chek, visit www.accu-chek.com
ACCU-CHEK, ACCU-CHEK AVIVA CONNECT, ACCU-CHEK AVIVA INSIGHT,
ACCU-CHEK CONNECT and ACCU-CHEK INSIGHT are trademarks of Roche.
© 2015 Roche Diabetes Care
www.accu-chek.com
Roche Diabetes Care GmbH
Sandhofer Str. 116
D-68305 Mannheim
27
INDUSTRY SYMPOSIA
Should SGLT2 Inhibitors Be An Integral
Part of a Personalized Treatment Plan
for Type 2 Diabetes?
Monday, 14 SEPTEMBER 2015 14:30 – 17:00
Loubatière Hall
14:30 – 14:40
Introduction and Welcome Guntram Schernthaner (Austria)
14:40 – 15:00
Updates on the Clinical and Physiologic Effects of SGLT2 Inhibition:
What Have We Learned? Guntram Schernthaner (Austria)
15:00 – 15:30
Expanding Treatment Options for Glycemic Reduction in Patients with
T2DM: Role of SGLT2 Inhibitors
Francisco Javier Ampudia-Blasco (Spain)
15:30 – 15:55
Non-glycemic Effects of SGLT2 Inhibitors: How Novel Antihyperglycemic .
Therapy May Improve Patient Outcomes
Ronan Roussel (France)
15:55 – 16:40
Putting It All Together: Practical Considerations for Using SGLT2 Inhibitors
in the Management of Patients with T2DM
John P. H. Wilding (UK)
16:40 – 16:58
Q&A Session Faculty Panel
16:58 – 17:00
Conclusions
John P. H. Wilding (UK)
Organised by: Medscape Education
supported by an independent educational grant from Janssen
28
INDUSTRY SYMPOSIA
One year with flash glucose monitoring –
Perspectives from different stakeholders
in diabetes care. What’s next?
Monday, 14 SEPTEMBER 2015 14:30 – 17:00
Sterne Hall
Chair: Professor Jan Bolinder (Sweden)
14:35 – 15:05
Clinical experience with FreeStyle Libre
Stig Attvall (Sweden)
15:05– 15:35
Ambulatory Glucose Profile (AGP) through the diabetes care continuum
Dr. med. Oliver Schubert (Germany)
15:35 – 16:05
The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue
in T1 Diabetes
Stephen Dixon and Dr. Pratik Choudhary (UK)
16:05 – 16:35
The Impact of AGP and FreeStyle Libre on the Patient – Clinician Dialogue
in T2 Diabetes
Dr. med. Oliver Schubert (Germany) 16:40 – 17:00
Panel Discussion
Professor Jan Bolinder and all Presenters
Organised by: Abbott
29
INDUSTRY MINI SYMPOSIA
What is the Optimized treatment
for T2DM patients?
Monday, 14 SEPTEMBER 2015 17:00 – 18:00
Schmidt Hall
17:00 – 17:10
Welcome Address of Chairman
Prof. Moon-Kyu Lee (Korea)
17:10 – 17:30
Gemigliptin: The Optimized DPP-4 inhibitor for T2DM Patients Prof. Soo Lim (Korea)
17:30 – 17:50
The Optimal Management in T2DM Patients with Renal Impairment
Prof. Eun-Jung Rhee (Korea)
17:50 – 18:00 Q&A and Closing
Organised by: LG Life Sciences
30
INDUSTRY SYMPOSIA
Advancing diabetes treatment and future perspectives
XXXXXX
Monday, 14 SEPTEMBER 2015 08:30 – 09:00
Pre-symposium breakfast
Chair: Host: Jiten Vora (UK)
Ramon Gomis (ES)
09:00 – 09:10 Welcome to Novo Nordisk symposium at EASD
Ramon Gomis (ES)
09:10 – 09:20 Introduction and update on basal insulin therapy
Jiten Vora (UK)
09:20 – 09:40 Opportunities from designer proteins
Peter Kurtzhals (DK)
09:40 – 09:55 Clinical profiles of new long-acting insulins and insulin
combination products
Thomas Pieber (AT)
09:55 – 10:10 Improving efficacy without compromising the risk of
hypoglycaemia
Athena Philis-Tsimikas (US)
10:10 – 10.25 Flexibility in dose timing matching patient needs
Luigi Meneghini (US)
10:25 – 10:55 Coffee break
10:55 – 11:10 Synergies of complementary drugs
John Buse (US)
11:55 – 12:30 Panel discussion
Organised by: Novo Nordisk
31
10:00 – 17:00
Bernard Hall
INDUSTRY MINI SYMPOSIA
The Metabolic Chaos of Lipodystrophy –
Finding the Order Within
Monday, 14 SEPTEMBER 2015 Keynote speaker: Prof. Abhimanyu Garg (USA)
17:00 – 17:05 Welcome and introduction
17:05 – 17:45 Keynote speech
Prof. Abhimanyu Garg (USA)
17:45 – 18:00
Questions and Answers
Organised by: Aegerion
32
17:00 – 18:00
Hodgkin Hall
INDUSTRY MINI SYMPOSIA
Challenges in Comprehensive
Lipid Management
Monday, 14 SEPTEMBER 2015 17:00 – 18:00
Pirart Hall
17:00 – 17:05
Welcome & Objectives
17:05 – 17:20
Cardiovascular Risk in Diabetes Patients: Just About Lipid Modification?
Peter J. Grant (United Kingdom)
17:20 – 17:35
Dyslipidemia and Atherogenicity in T2DM: Looking Beyond the Obvious
Alberto Zambon (Italy)
17:35 – 17:50
What is the Role of CETP in Lipid Metabolism?
José María Mostaza Prieto (Spain)
17:50 – 18:00
Expert Panel
Organised by: Eli Lilly and Company
33
INDUSTRY MINI SYMPOSIA
SAVE THE DATE
INDUSTRY Programme
on the occasion of the
52nd Annual Meeting
of the European Association
for the Study of Diabetes
Munich
12 – 16 September 2016
12 September 2016
Industry Symposia & Industry Mini Symposia
13 – 15 September 2016
Industry Exhibition
15 September 2015
Industry Evening Symposia
INTERPLAN
media & service gmbh
34
www.easd-industry.com
INDUSTRY EVENING SYMPOSIA
GLP-1 Receptor Agonists:
Liraglutide 3.0 mg in weight management
Thursday, 17 September 2015 19:00 – 20:30
Loubatière Hall
19:00 – 19:05 Welcome and introduction
Joanna Uddén Hemmingsson (Sweden)
19:05 – 19:20 The role of GLP-1 in weight management: targeting central nervous
system appetite regulation
Darleen Sandoval (USA)
19:20 – 19:35 Optimising the dose for weight management: phase 2 results
Nick Finer (UK)
19:35 – 20:00 SCALE Obesity and Prediabetes & SCALE Maintenance: key results
Carel Le Roux (Ireland)
20:00 – 20:15 SCALE Diabetes: key results
Tina Vilsbøll (Denmark)
20:15 – 20:30 Panel discussion
All faculty
Organised by: Novo Nordisk
35
INDUSTRY EVENING SYMPOSIA
EMPA-REG OUTCOME®:
Implications for management of patients
with Type 2 Diabetes
Thursday, 17 September 2015
19:00 – 20:30
Meyer-Schwickerath Hall
19:00 – 19:05
Welcome and introduction
Lars Rydén (Sweden)
19:05 – 19:40
Exploring the results of EMPA-REG OUTCOME®
Bernard Zinman (Canada)
19:40 – 20:20
Treatment of Type 2 Diabetes and cardiovascular risk in the context
of EMPA-REG OUTCOME®
Lars Rydén (Sweden)
Sanjay Kaul (USA)
Lawrence Leiter (Canada)
Naveed Sattar (UK)
20:20 – 20:30
Conclusion, summary and close
Lars Rydén (Sweden)
Organised by: Boehringer Ingelheim & Eli Lilly and Company
36
It’s a pill with benefits I could appreciate?
THAT
Find out more at Booths
B10:21 and B10:20
SPEAKS
TO
DOCTOR
JARDIANCE, an SGLT2
inhibitor for adults with
type 2 diabetes, provides1:
SYNJARDY, a new SGLT2 inhibitor +
metformin combination therapy for
adults with type 2 diabetes, provides6:
• Significant HbA1c reduction
with the additional benefit of
weight loss2-5*†
• The efficacy of both empagliflozin
and metformin in 1 pill6*†
• Efficacy when added to a
range of background treatments,
including insulin3-5
• Flexible dosing options to
individualise treatment6
• The convenience of a single-pill
combination for your patients
• Convenient once-daily oral dosing
*JARDIANCE and SYNJARDY are not indicated for weight loss.
†
Weight change was a secondary endpoint in clinical trials.
Now those are benefits your patients could appreciate.
Issued June, 2015
Jardiance (empagliflozin) 10 mg, 25 mg
film-coated tablets, prescription only
SGLT2 inhibitor.
Therapeutic indications:
Jardiance is indicated in the treatment
of type 2 diabetes mellitus to improve
glycaemic control in adults as
monotherapy: when diet and exercise
alone do not provide adequate glycaemic
control in patients for whom use of
metformin is considered inappropriate
due to intolerance; add-on combination
therapy: in combination with other
glucose-lowering medicinal products
including insulin, when these, together
with diet and exercise, do not provide
adequate glycaemic control.
Contraindications:
Hypersensitivity to the active substance
or any of the excipients.
Special warnings and precautions for
use: Should not be used in patients with
type 1 diabetes or diabetic ketoacidosis;
patients with ESRD or in patients with
dialysis; should not be initiated in patients
with eGFR below 60 mL/min/1.73 m2;
caution should be exercised in patients
with a risk for volume depletion, such as
patients aged 75 years or older, those
on anti-hypertensive therapy with a
history of hypotension, with well known
cardiovascular disease. In patients
tolerating empagliflozin whose eGFR falls
persistently below 60 mL/min/1.73 m2
or CrCl below 60 mL/min, the dose
of empagliflozin should be adjusted
to or maintained at 10 mg once daily.
Empagliflozin should be discontinued
when eGFR is persistently below
45 mL/min/1.73 m2 or CrCl persistently
below 45 mL/min.
This drug is subject to additional
monitoring. HCPs are asked to report any
suspected adverse reactions.
May, 2014
MARKETING
AUTHORISATION HOLDER
Boehringer Ingelheim International
GmbH, Binger Str. 173, D-55216 Ingelheim
am Rhein, Germany.
Further information on warnings and
precautions on the use, interactions
with other medical products and
contraindications can be found in the
Summary of Product Characteristics.
This is the prescribing information
approved for use in Sweden. Please refer
to your local prescribing information as
this information may vary from country
to country.
Synjardy (empagliflozin/metformin
hydrochloride), film-coated tablets,
prescription only.
Synjardy 5 mg/850 mg. Each tablet
contains 5 mg empagliflozin and 850 mg
metformin hydrochloride.
Synjardy 5 mg/1,000 mg. Each tablet
contains 5 mg empagliflozin and 1,000
mg metformin hydrochloride.
Synjardy 12.5 mg/850 mg. Each tablet
contains 12.5 mg empagliflozin and 850
mg metformin hydrochloride.
Synjardy 12.5 mg/1,000 mg. Each
tablet contains 12.5 mg empagliflozin and
1,000 mg metformin hydrochloride.
SGLT2 inhibitor/Biguanide.
Therapeutic indications:
Synjardy is indicated in adults aged 18
years and older with type 2 diabetes
mellitus as an adjunct to diet and
exercise to improve glycaemic control in
patients inadequately controlled on their
maximally tolerated dose of metformin
alone, in patients inadequately controlled
with metformin in combination with other
glucose-lowering medicinal products,
including insulin, in patients already
being treated with the combination
of empagliflozin and metformin as
separate tablets.
References: 1. JARDIANCE [summary of product characteristics]. Ingelheim am Rhein, Germany: Boehringer
Ingelheim Pharmaceuticals, GmbH; 2014. 2. Roden M et al. Lancet Diabetes Endocrinol. 2013;1:208-219.
3. Häring HU et al. Diabetes Care. 2014;37:1650-1659. 4. Häring HU et al. Diabetes Care. 2013;36:3396–3404.
5. Rosenstock J et al. Poster presented at 49th Annual Meeting of the European Association for the Study of
Diabetes; Sept. 23–27, 2013; Barcelona, Spain. 6. SYNJARDY [summary of product characteristics]. Ingelheim
am Rhein, Germany: Boehringer Ingelheim Pharmaceuticals, GmbH; 2015.
37
Contraindications:
Diabetic ketoacidosis, diabetic precoma, renal failure or renal dysfunction
(creatinine clearance <60 mL/min),
acute conditions with the potential to
alter renal function such as: dehydration,
severe infection, shock. Acute or chronic
disease which may cause tissue hypoxia
such as: cardiac or respiratory failure,
recent myocardial infarction, shock.
Hepatic impairment, acute alcohol
intoxication, alcoholism.
This drug is subject to additional
monitoring. HCPs are asked to report any
suspected adverse reactions.
June, 2015
MARKETING
AUTHORISATION HOLDER
Boehringer Ingelheim International
GmbH, Binger Str. 173, D-55216 Ingelheim
am Rhein, Germany.
Further information on warnings and
precautions on the use, interactions
with other medical products and
contraindications can be found in the
Summary of Product Characteristics.
This is the prescribing information
approved for use in Sweden. Please refer
to your local prescribing information as
this information may vary from country
to country.
To learn more about JARDIANCE and SYNJARDY,
please contact your local representative.
Please see full Prescribing Information for additional information.
INDUSTRY EVENING SYMPOSIA
The TECOS CV Safety Trial and the Lessons
Learned for Treatment of Patients with
Type 2 Diabetes and Cardiovascular Disease
Thursday, 17 September 2015 19:00 – 20:30
Kimmelstiel Hall
Co-Chairs:
Niko Marx (Germany)
Juris Meier (Germany)
19:00 – 19:05 Welcome
Niko Marx (Germany) and Juris Meier (Germany)
19:05 – 19:20 Continuing our Understanding of the Role DPP-4 Inhibitors Play in the
Cardiovascular Patient with Type 2 Diabetes
Richard Gilbert (Canada)
19:20 – 19:30 Q and A
19:30 – 19:55 TECOS CV SAFETY TRIAL: New Data from the CV Safety Trial for Sitagliptin
Rury Holman (UK)
19:55 – 20:05 Q and A
20:05 – 20:25 Faculty Specialty Dialogue: Lessons Learned for the Treatment of Patients .
with Type 2 Diabetes and Cardiovascular Disease
All faculty
20:25 – 20:30 Closing Comments
Niko Marx (Germany) and Juris Meier (Germany)
Organised by: Merck Sharp & Dohme
38
INDUSTRY EVENING SYMPOSIA
The Patient in Mind:
new perspectives on injectable therapy
for type 2 diabetes
Thursday, 17 September 2015 19:00 – 20:30
Elite Hotel Marina Tower
Chair: Michael Nauck (Germany)
19:00 – 19:05
Introduction/Opening
Michael Nauck (Germany)
19:05 – 19:25
Understanding the T2DM patient transition to injectable therapy
Melanie Davies (UK)
19:25 – 19:45
What drives treatment persistence and preference in T2DM?
Francesco Giorgino (Italy)
19:45 – 20:10
Can weekly GLP-1 RAs influence the current perspective of injectable therapies? A commentary on the latest data Michael Nauck (Germany)
20:10 – 20:30
Panel discussion + Wrap up Michael Nauck (Germany)
Please note this meeting is by registration only.
Please contact Lilly staff for further details.
Organised by: Eli Lilly and Company
39
INDUSTRY
SYMPOSIA
Find
your EVENING
perfect
place
to stay in Munich!
http://hotels2016.easd-industry.com/
Username Password hotels2016
Munich*16
The hotel capacities are limited and it is recommended
to arrange your booking early.
For further details, please contact
INTERPLAN
Congress, Meeting & Event Management AG
Landsberger Str. 155
80687 Munich, Germany
Phone: +49 89 - 54 82 34-9055
Email: hotels2016@interplan.de
BADGES DURING SYMPOSIA DAYS
Due to safety reasons, the entrance to the conference site during the industry symposia on the occasion of the
51st EASD Annual Meeting will be strictly controlled.
This means that each regular attendee of the symposia day has to be identified as authorised by wearing a badge.
Our security staff will accept the following types of badges or name labels only:
• Regular delegate badge
• Regular exhibitor badge
• Special name tags, provided by the company itself, showing the status of the person wearing:
“Invited by …, Guest of …, Technician of…“
Type of
Badge
Access to
Industry
Symposia
14.09.15
Access to the
Scientific
Sessions
15.– 18.09.15
Access to
Industry Evening
Symposia
17.09.15
Access to the
Industry
Exhibition
15.– 17.09.15
Speaker / Delegate
registered for the Scientific
Programme of the
EASD Annual Meeting
Congress
Badge
✔
✔
✔
✔
Speaker / Delegate
registered as an exhibitor
for the Industry Exhibition
of the EASD Annual Meeting
Exhibitor
Badge
✔
✘
✔
✔
Company
Speaker / Delegate
not registered for the
EASD Annual Meeting
Own
Company
created
Badge
✔
✘
✘
✘
Type of Delegate
41
IMPRINT
INTERPLAN
media & service gmbh
c/o INTERPLAN AG
Landsberger Strasse 155
80687 Munich
Germany
Phone: +49 (0) 89 54 82 34-67
Fax: +49 (0) 89 54 82 34-45
Email: easd2015@interplan.de
Website: www.interplan.de
Picture on page 7: © Stockholmsmässan, Karl Gabor
Each company is responsible for the content of their symposium.
Status: July 2015. All subjects to change.
42
LET’S TALK ABOUT helping your patients feel better about starting basal insulin.
Introducing ABASAGLAR — a once-daily insulin glargine with clinical benefits you may
find familiar and an initiation experience your patients may find appealing.
Visit Lilly booth B10:20 and BI booth B10:21 to learn more.
ABASAGLAR 100 units/mL solution for injection (insulin glargine)
Cartridge, pre-filled pen (KwikPen™)
This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions.
ATC code: A10AE04
Drugs used in diabetes. Insulins and analogues for injection, long-acting.
Indications: Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.
Contraindications: Hypersensitivity to the active substance or to any of the excipients.
Warnings: ABASAGLAR is not the insulin of choice for the treatment of diabetic ketoacidosis. Instead, regular insulin administered intravenously
is recommended in such cases. In case of insufficient glucose control or a tendency to hyperglycaemic or hypoglycaemic episodes, the patient's
adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before
dose adjustment is considered.
Transferring a patient to another type or brand of insulin should be done under strict medical supervision. Changes in strength, brand (manufacturer),
type (regular, NPH, lente, long acting, etc.), origin (animal, human, human insulin analogue) and/or method of manufacture may result in the need for
a change in dose.
Insulin administration may cause insulin antibodies to form. In rare cases, the presence of such insulin antibodies may necessitate adjustment of the
insulin dose in order to correct a tendency to hyper- or hypoglycaemia.
Date of revision of the text: 17 February 2015
For further information and prices see www.fass.se
Rx, not F
This text is based on the Swedish prescribing information. Please contact your local Lilly representative for information relevant to your country.
Eli Lilly Sweden AB, Box 721, 169 27 Solna. 08-737 88 00. www.lilly.se.
Date of last SmPC update: 2015-04-16
SEDBT01535 02-JUN-2015
Join us at this state-of-the-art symposium and be one of the first to discuss the results
of the EMPA-REG OUTCOME™ trial with leading experts
0
0
5
:2
20
:4
19
:0
19
0
:0
19
tro
in
nt s OU
s w fo T
ith r m CO
Ty ana ME
pe ge ™
2D m :
iab ent
et
es
n
yd
é
rs
R
La
)
we
de
n
(S
(U
K
)
te
r
)
da
)
SA
na
(C
a
da
)
na
(C
a
in
m
an
ar
dZ
re
nc
eL
ei
at
ta
r
dS
ve
e
Na
La
w
te
Me
m
ye
rbe
du
of plo
S
ct
ch
r2
EM rin
io
wi
n
01
g
ck
PA t
er
5,
-R he
at
EG re
19
hH
OU sul
:0
al
l, S
0–
TC ts
La
t
rs
oc
20
OM
Ry
kh
:3
E™
dé
ol
0;
m
n
(S
I
Ch
n
we
te
Tr
rn
de
air
at
n)
ca eat
:L
i
B
o
er
na
of rdi me
ar
na
lF
Pa EM ova nt o
sR
rd
a
irs
Zi
Au ne PA scu f T
nm
yd
an
die l di -R la yp
dC
an
én
nc scu EG r ri e 2
(C
on
e Q ss OU sk Di
an
gr
ad
es
&A ion TC in abe
a)
sC
OM the te
s
en
E™ co a
tre
nt nd
,S
ex
we
t
Co
de
La
n
an nc
rs
d c lus
Ry
lo ion
dé
se ,
S
n
an
su
(S
j
m
ay
we
m
K
de
au
ar
Be
n)
l(
y
rn
U
Ex
nd
ea
W
el
co
m
EM
Im PA
of plic -R
pa at E
17
Se
tie ion G
p